GlassScriptPhysician profile
Jillian Mackenzie Blanco
NPI 1548941172
$2,225.81
in general payments reported to CMS, 2019-2025
18 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $612 · 2024: $1,456 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $916.76 | 2023-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $491.83 | 2023-2025 | Biktarvy |
| Emd Serono, INC. | $277.24 | 2023-2024 | Serostim, Serostim |
| Glaxosmithkline, LLC. | $117.42 | 2023 | Arexvy |
| Idorsia Pharmaceuticals US INC | $61.48 | 2023-2024 | Quviviq |
| Abbvie INC. | $50.25 | 2023-2024 | |
| Pfizer INC. | $44.40 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $37.23 | 2024 | Spravato |
| Merck Sharp & Dohme LLC | $29.13 | 2023 | Delstrigo, Pifeltro, Dificid |
| Napo Pharmaceuticals INC | $26.70 | 2024 | Mytesi |
| Endo USA, INC. | $25.92 | 2024 | Xiaflex, Aveed |
| Lilly USA, LLC | $24.42 | 2024 | Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $22.96 | 2023 | Rexulti |
| Hologic Sales and Service, LLC | $22.59 | 2025 | Aptima, Thinprep 2000 Processor |
| Halozyme INC | $20.68 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.73 | 2023 | Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $18.86 | 2025 | Nuzyra |
| Collegium Pharmaceutical, INC. | $18.21 | 2023 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Blanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.